Lyudmila Bazhenova, MD of the University of California, San Diego discusses osimertinib & small cell transformation. There is a very important discovery in the recent years about the fact that patients who have progressed from prior EGFR TKI can transform into small cell. If the patient, at the time of diagnosis of lung cancer, has deficiencies in P53 and RB1, they are 43 times more likely to develop small-cell transformation upon progression. Hence, biopsy should be done for these patients. This is in order to exclude the small cell transformations. Patients with this kind of transformation should be given small-cell appropriate chemotherapy regimes, like platinum etoposide or platinum irinotecan.
Osimertinib & Small Cell Transformation
